Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2025, Vol. 30 ›› Issue (2): 232-237.doi: 10.12092/j.issn.1009-2501.2025.02.010

Previous Articles     Next Articles

Analysis of risk factors for intolerance of valsartan with Sakubatrol in patients with heart failure

WANG Jia1, WANG Lei2, XU Binfa3, LIU Feng3, WEN Xin1, CHEN Min4, GAO Yinsi5   

  1. 1 Department of Pharmacy, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 2 Department of Medical Insurance, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China; 3 Department of Quality and Performance Management, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 4 Department of Medical Records Room, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China; 5 Department of Business Development, the Third Hospital Affiliated of Anhui Medical University, Hefei 230061, Anhui, China
  • Received:2024-07-30 Revised:2024-09-28 Online:2025-02-26 Published:2025-02-05

PDF (PC)

232

Abstract:

AIM: To investigate the risk factors for intolerance to sacubitril/valsartan in the treatment of heart failure. METHODS: A total of 124 heart failure patients hospitalized in our hospital from May 2023 to May 2024 were collected. Logistic regression analysis and nomogram analysis were used to identify the risk factors for drug tolerance. RESULTS: 22 patients exhibited intolerance, with low blood pressure being the primary cause (P<0.05). Multivariate regression analysis found that patients with a low BMI (OR 95%CI 1.814(1.385-2.525)) and those without concomitant right heart failure (OR 95%CI 4.998(1.552-17.301)) were more likely to experience drug intolerance. The model had a stable C-index of 0.923 (95%CI=0.863-0.975). CONCLUSION: Low BMI and absence of right heart failure are risk factors affecting the tolerance to sacubitril/valsartan, which has certain value for guiding clinical treatment. Large-sample clinical studies are still needed to confirm these findings.

Key words: heart failure, sacubitril/valsartan, tolerance, risk factor

CLC Number: